S oft tissue sarcomas (STS) are a complex heterogeneous collection of more than 50 neoplasms of mesenchymal origin. According to the American Cancer Society, in 2015 approximately 11,930 patients in the Unites States will be diagnosed with STS, and nearly 4,870 will die from the disease. Surgery is the mainstay of therapy. For metastatic STS, cytotoxic chemotherapeutic agents such as doxorubicin or gemcitabine plus docetaxel have been used with response rates of approximately 25%, and overall survival (OS) of 12 to 18 months. 1, 2 Whenever possible, treatments are now tailored to the histologic subtype, tumor characteristics, molecular signature, and patient performance status. Liposarcoma is among the most common sarcoma subtypes, with average annual, age-adjusted incidence of 0.4 to 1.1 per 100,000 persons dependent on gender and race. 3 Liposarcomas are a heterogeneous group of adipocytic neoplasms that are generally resistant to chemotherapy. This review will focus on management of liposarcomas and discuss novel targets and therapies directed toward them that are being tested in clinical trials.
LIPOSARCOMAS
Liposarcomas are neoplasms of adipocytes that normally grow slowly and present as a painless nonulcerated enlarging mass. They are subclassifıed into distinct categories dependent on their histology, molecular signature, and behavior 4 :
• Well-differentiated/atypical lipomatous tumor • Dedifferentiated liposarcoma • Myxoid (round cell) liposarcoma • Pleomorphic liposarcoma • Liposarcoma, not otherwise specifıed Rarely, a specimen may have a combination of morphologic subtypes; this is referred to as mixed liposarcoma.
ATYPICAL LIPOMATOUS TUMOR/WELL-DIFFERENTIATED LIPOSARCOMA
Atypical lipomatous tumor (ALT) or well-differentiated liposarcoma (WDLS) is the least aggressive of the malignant forms of liposarcoma and represents 40% to 45% of the liposarcomas that are diagnosed. 5 Microscopically, they consist of scattered lipoblasts with a single atypical nucleus surrounded by large intracytoplasmic vacuoles in a background of adipocytes. 4 ALT/WDLS are usually indolent and tend not to metastasize, but can recur locally. However, if they undifferentiate into the dedifferentiated form, they exhibit an aggressive phenotype and are likely to metastasize. 6 The retroperitoneum and extremities are common primary sites, but they can also occur within the mediastinum and parates-ticular region. 7 ALT/WDLS within the retroperitoneum, mediastinum, and spermatic cord are more likely to recur and result in signifıcant morbidity and mortality from local disease. 6 Gene expression profıling when compared to normal fat has indicated overexpression of several genes in the 12q12-15 amplicon, including CDK4 and MDM2. 7 MDM2 is a ubiquitin ligase that binds to the transactivation domain of p53 and promotes its degradation.
DEDIFFERENTIATED LIPOSARCOMA
Dedifferentiated liposarcoma (DDLS) is the second most common type of liposarcoma diagnosed. DDLS is cellular and consists of nonlipogenic sarcoma that transitions abruptly within an ALT. 4 DDLS has morphologic and molecular similarities to ALT/WDLS but behaves aggressively. DDLS has a higher rate of recurrence, with 20% to 30% distant metastasis, and a 6-fold higher risk of death compared to ALT/WDLS. 8, 9 Many of the gene alterations found in WDLS are also found in DDLS. 7 For example, both CDK4 and MDM2 are overexpressed in both of these diseases. Genomic alterations of 207 STS, which included 50 DDLS specimens, confırmed the prior fındings of amplifıcations within 12q12-15, including CDK4 and MDM2. 10 WDLS and DDLS respond very poorly to chemotherapy and new treatment options are desperately needed. 11
CDK4 and MDM2 Inhibitors
CDK4 -Palbociclib. CDK4 is amplifıed in more than 90% of WDLS and DDLS cases, making it an opportune target in this disease subtypes. Preclinically, palbociclib (PD0332991), a CDK4/6 inhibitor, induces a G1 cell cycle arrest in liposarcoma cell lines that overexpress CDK4. 10 A phase I trial with palbociclib in patients with advanced solid malignancies identifıed one patient each with ATL/WDLS and DDLS who had stable disease lasting several years at a dose of 200 mg daily for 14 consecutive days in 21-day cycles. 12 This led to an open-label phase II trial for patients with WDLS and DDLS. Patients' tumors were required to have CDK4 amplifıcation and retinoblastoma protein (RB) expression, which is the downstream target for CDK4. Preclinically, RB expression was required for palbociclib activity. 10 Among the 30 patients enrolled (fıve with WDLS and 25 with DDLS), the trial reported a 12-week progression-free survival (PFS) rate of 66%, surpassing the primary endpoint criteria of 40%. Signifıcant hematologic toxicities were observed, including grade 3 and 4 anemia (17%), thrombocytopenia (30%), neutropenia (50%), and febrile neutropenia (3%). 13 The results of a phase II study with a modifıed oral dose of 125 mg daily for 21 consecutive days in 28-day cycles (NCT01209598) were reported at the 2013 ASCO Annual Meeting, which indicated a comparable 12-week PFS but with reduced bone marrow toxicity. 14 CDK4 -LEE001 and LY2835219. Other CDK4 inhibitors are in clinical trials, including LEE001 and LY2835219. These agents exhibit a somewhat different toxicity profıle, with neutropenia and QTc prolongation more common with LEE001 and gastrointestinal toxicity more common with LY2835219. 15, 16 Stable disease was noted in patients with liposarcoma, although the complete results with these agents in this disease are pending publication.
One unresolved question is whether there exists a biomarker to predict clinical benefıt. Rb expression appears to be necessary, but its presence is not predictive of benefıt.
MDM2 targeting.
Recently, it has been shown that CDK4 inhibition induces a G1 cell cycle arrest in all liposarcoma cells. However, only some of these cells undergo a process of cell death called cellular senescence. The proteolytic turnover of MDM2 appears critical for the induction of cellular senescence induced by palbociclib and by suppression of CDK4 by siRNA. Furthermore, the loss of MDM2 expression induced by CDK4 inhibition appears to be dependent on the baseline expression of ATRX. An examination of MDM2 loss in liposarcoma patients treated with palbociclib has been shown to correlate with prolonged stable disease; whereas patients with no change in MDM2 expression had rapid disease progression with this therapy. The importance of baseline ATRX expression, and the loss of MDM2 expression as a maker of clinical benefıt to CDK4 inhibitors in liposarcoma (as well as other tumor types), will require validation in future clinical trials. 17 MDM2 gene amplifıcation or protein overexpression has been demonstrated in several cancer types, including DDLS. 18 Disruption of MDM2 and p53 interaction in cancer types with wild-type p53 and MDM2 overexpression has shown promise in vitro and in vivo. Nutlins are a class of imidazoline compounds that have been shown to have potent and selective activity against MDM2. 19 In preclinical studies, nutlin-3a was the fırst drug to show potent in vitro effects in liposarcoma cell lines with amplifıcations and overexpression of MDM2. 7 This drug induced both cell KEY POINTS ⅐ Sarcomas are rare malignancies of mesenchymal origin that represent a heterogeneous group of over 50 subtypes, of which liposarcomas are one of the most common subtype. ⅐ Liposarcomas contain at least four distinct subtypes for which treatment has to be tailored. ⅐ Well-differentiated liposarcoma is the least malignant form, does not respond to chemotherapy, and tends to recur locally. ⅐ Dedifferentiated liposarcoma has some response to chemotherapy and, like well-differentiated liposarcoma, contains amplification/overexpression of murine double minute 2 and cyclin-dependent kinase 4, inhibition of which have shown promise in early-phase clinical trials. ⅐ Retrospective data indicate trabectedin to have activity in myxoid (round cell) liposarcoma, which is currently under U.S. Food and Drug Administration review for this indication.
cycle arrest and apoptosis in these cells, which were also p53 wild-type. 19
MDM2-RG7112. RG7112 was the fırst nutlin inhibitor to be tested clinically. In a proof-of-concept study, 20 chemotherapy-naive patients with primary or relapsed WDLS (11 patients) or DDLS (9 patients) were enrolled in the neoadjuvant setting. Patients were treated with up to three cycles with 1,440 mg/m 2 of RG7112 for 10 days on a 28-day cycle schedule. Two of the 20 patients carried missense mutations in TP53 and 14 of 17 had MDM2 amplifıcations (three did not have adequate samples). Patients underwent paired biopsies before and on day 8 of treatment. p21 expression, a marker of p53 function, increased 3.48-fold in tumor tissue as measured by immunohistochemistry, while macrophage inhibitory cytokine-1 (MIC-1) levels, a marker of apoptosis and p53 induction, increased in blood. p53 expression and MDM2 transcripts also increased by 4.86-and 3.03-fold compared to baseline, respectively. Nineteen patients received at least one cycle of RG7112, of which ten and fıve completed three and two cycles, respectively. One patient achieved a partial response, 14 had stable disease, and fıve experienced disease progression (all of whom had DDLS). 20 Ten patients underwent surgical resection at a median of 34.5 days after the last dose of RG7112, of which eight had a complete resection and two had partial resections. 20 Patients with partial resection received three cycles of adjuvant treatment and maintained stable disease.
Ten serious treatment-related adverse events (AEs) were observed in seven patients, all of which were hematologic in nature. Grade 3 or 4 AEs included neutropenia (30%), febrile neutropenia (5%), thrombocytopenia (15%), nausea (5%), emesis (10%), diarrhea (5%), and general deterioration (5%). One patient died of nontreatment-related postoperative hemorrhagic complications. Hematologic AEs, including thrombocytopenia, led to treatment delays in many patients; three had to discontinue treatment. All patients recovered from their hematologic AEs and there were no treatmentrelated bleeding complications. 20 RG7112 treatment in mice and monkeys also resulted in thrombocytopenia by promoting megakaryocyte progenitor cell destruction by apoptosis and inhibition of DNA synthesis during endomitosis, a key step for platelet production. 21 MDM2-SAR405838. SAR405838 is an oral spirooxindole derivative antagonist that binds to MDM2 with a Ki of 0.88 nmol/L, has high specifıcity, and has a dissociation constant of 9.4 nmol/L. A cocrystal structure of SAR405838 and MDM2 indicates that SAR405838 mimics three key p53 amino acids and binds to the unstructured N-terminus of MDM2 to achieve high affınity. 22 SAR405838 activated wildtype p53 function in vitro and in xenograft tumor tissue of solid tumors, leading to p53-dependent cell cycle arrest and/or apoptosis. SAR405838 resulted in transcriptional upregulation of PUMA, a transcriptional target of p53, induction of apoptosis, and complete tumor regression in SJSA-1 osteosarcoma xenograft model. 22 A fırst-in-human phase I trial in patients with solid tumors evaluated once-daily and weekly schedules of SAR405838. 23 Only patients with DDLS were included in the maximum tolerated dose (MTD) expansion cohort. Sixty-eight patients were enrolled in the trial, of which 43% had liposarcoma. At the time of publication, 65 patients had discontinued study participation and three remained on study. Of the 65 patients, 47 discontinued participation because of disease progression, nine because of AEs, and nine for other reasons. Median duration of treatment was 42 days and MTD was established at 300 mg orally daily. Within the expansion cohort, 21 patients with DDLS were treated at 300 mg orally daily. The most common treatmentrelated AEs within this cohort included nausea (38%), fatigue (33%), diarrhea (24%), and thrombocytopenia (14%). Eight patients discontinued treatment because of AEs. Of note, no dose-limiting toxicities were observed on the weekly schedule of SAR405838. 23 Pharmacokinetic studies indicated a T max of approximately 4 hours and half-life of nearly 16 hours. Plasma MIC-1 protein concentration correlated positively with SAR405838 exposure. Interestingly, a lower platelet count correlated with higher SAR405838 levels on a daily administered schedule, but a higher C max achieved on the weekly schedule did not correlate with lower platelet counts. Overall, the best response was stable disease in 32 patients (47%), of which 13 patients (19.1%) had stable disease at 12 weeks. In the MTD expansion cohort with DDLS, 11 of 21 patients (52%) had stable disease as best response. 23 
MYXOID (ROUND CELL) LIPOSARCOMA
Myxoid (round cell) liposarcomas (MRCL) mostly arise in deep soft tissue of the extremities in patients who tend to be younger than those with other sarcoma subtypes. MRCL represents a single entity with variable round cell component and accounts for 30% to 35% of liposarcomas. 24 Round cell liposarcoma is considered a more aggressive subtype of myxoid liposarcoma, with greater than 5% round cell component carrying an unfavorable prognosis. 25, 26 Unlike other tumors, MRCL tends to spread to serosal surfaces, bones, the abdominal cavity, and other soft tissues, even in the absence of lung disease. 27 Microscopic evaluation identifıes tumors composed of uniform round-to-oval primitive nonmesenchymal cells and a variable number of monovacuolated lipoblasts. More than 90% of MRCL tumors contain the 12q13 and 16p11 translocation that leads to the FUS-DDITR (TLS-CHOP) fusion. Fused in sarcoma (FUS) protein, EWSR1, and TAF15 belong to the FET family of proteins and are involved in regulation of transcription and RNA splicing. DDIT3 is a leucine zipper containing transcription factor and is a member of the C/EBP family that plays a role in adipocyte differentiation and cell cycle control. 28 The fusion protein is thought to result in malignant transformation by favoring adipocyte differentiation over proliferation. These tumors are also characterized by mutations in PIK3CA, encoding the catalytic subunit of phosphatidylinositol 3-kinase (PI3K). 10 In a series of 71 patients with MRCL, 13 had point mutations in PIK3CA. These mutations were clustered in two domains, the helical domain (E542K and E545K) and the kinase domain (H1047L and H1047R). Interestingly, patients whose tumors harbored mutations in PIK3CA had a shorter duration of disease-specifıc survival than did those with wild-type PIK3CA (p ϭ 0.036, log-rank test). 10 Surgery alone or with radiation therapy is the mainstay of treatment, but despite appropriate treatment for local disease, nearly 40% of patients experience disease relapse. 29 Although MRCL is relatively more chemotherapy-sensitive compared to other STS, median survival is 2 years in the advanced disease setting. 30 
Trabectedin
Apart from chemotherapy, trabectedin (ET-743), a marine alkaloid, is approved in Europe as second-line treatment for advanced STS and is a promising agent, particularly in MRCL. Trabectedin has two known functions: 1) It binds to DNA within the minor grove of the double helix, causing a conformational change that likely changes its interactions with DNA-binding proteins, and 2) it causes doublestranded DNA breaks by interaction with transcriptioncoupled nucleotide excision repair complex. Owing to its ability to alter DNA-protein interaction, it is not surprising that trabectedin specifıcally inhibited type I and II TLS-CHOP transcripts from binding to their cognate target promoters in an MRCL xenograft model that impeded TLS-CHOP function. 31 Recent evidence has suggested that trabectedin also affects the tumor microenvironment by targeting monocytes and macrophages that have protumoral functions, including production of growth factors, neoangiogenesis, increased protease activity, and support in tumor cell dissemination. [32] [33] [34] [35] Fifty-one patients with advanced myxoid liposarcoma treated with trabectedin on a compassionate-use basis were analyzed retrospectively and found to have an overall response of 51%, including two patients who achieved a complete response. Median PFS was 14 months and PFS at 6 months was 88%. 24 In a single-center retrospective study of 21 patients treated with trabectedin for a median of four cycles, an objective partial response was achieved in three patients (14%) and eight patients (38%) achieved stable disease for a median duration of 4.5 months. 36 The benefıt of trabectedin in other liposarcoma subtypes remains to be defıned.
PLEOMORPHIC LIPOSARCOMA
Pleomorphic liposarcoma (PLS) represents approximately 5% to 15% of liposarcomas 37 and usually presents in adults within the lower extremity. 38 PLS pathologically exhibits large, multivacuolated pleomorphic lipoblasts. 39 PLS is associated with a poor prognosis, with high local recurrence and distant metastasis in the range of 30% to 35%. 40 Because of the rarity of the disease, treatment data within this particular subtype is limited. A retrospective study reviewed response to chemotherapy in 39 patients with unresectable or metastatic PLS. 41 Of the 32 patients assessable for response, one (3%) had a complete response, 11 (34.5%) had a partial response, and nine (28%) had stable disease, with a median follow-up of 62 months. The median PFS and OS were 4.3 and 14 months, respectively. The overall objective response rate was 37%. Interestingly, anthracycline-based regimens did not result in an improved response rate compared to nonanthracycline-based therapies. 41 
CHEMOTHERAPY AND LIPOSARCOMA SUBTYPE SENSITIVITY
Overall, liposarcomas do not respond well to systemic cytotoxic chemotherapy. The Royal Marsden study addressed the subtype-specifıc sensitivity to chemotherapy in a retrospective analysis of a prospectively maintained database of patients treated between August 1989 and June 2004. Of the 88 patients with liposarcoma treated, 94% of patients received fırst-line chemotherapy for metastatic disease or for local recurrence. Thirty percent received doxorubicin and 17% received ifosfamide as monotherapy, while 34% received the combination. Of the subtypes treated, the most response rates were observed in the myxoid subtype (48%), while PLS (33%), DDLS (25%), and round cell liposarcoma (17%) achieved some response, in contrast to WDLS which had none. Combination chemotherapy with doxorubicin and ifosfamide resulted in the greatest response rates across subtypes.
Another large retrospective study of 208 patients, which focused on patients with advanced WDLS and DDLS from 11 participating institutions, identifıed that 85 patients (41%) received combination chemotherapy and 123 patients (59%) received single-agent chemotherapy. 43 The majority of patients (82%) received anthracycline-based therapy. Only 21 patients (12%) achieved an objective response, all of whom received anthracyclines. With a median follow-up of 28 months, median PFS and OS were 4.6 and 15.2 months, respectively. A trend toward a higher median PFS in WDLS (8.7 months) compared to DDLS (4 months) was noted. On multivariate analysis, age and performance status (PS) were the sole factors that independently associated with PFS, while grade and PS associated with OS. 43 
SUMMARY AND FUTURE DIRECTIONS
Although surgical resection remains the cornerstone for localized disease, treatment for unresectable or metastatic disease is highly dependent on the liposarcoma subtype. For patients with rapidly growing WDLS or DDLS, doxorubicinbased regimens can be considered as a treatment option, although response rates remain low. In contrast, for patients with MRCL, doxorubicin-based chemotherapy is the treatment of choice and trabectedin (where available) can also be considered as a treatment option. The role of PIK3CA inhibitors in this disease remains to be defıned, but the opening of MATCH trials through the National Cancer Institute with agents targeting PIK3CA may soon answer this question. The importance of trabectedin and newer cytotoxic agents, such as eribulin in liposarcoma subtypes other than MRCL, continues to be defıned. For PLS, chemotherapy remains the treatment of choice, although the prognosis in this setting is poor. Palbociclib, a CDK4/6 inhibitor, which was recently approved in combination with letrozole for patients with estrogen receptor (ER)-positive advanced breast cancer, is active in patients with WDLS/DDLS. With this agent, some patients achieve prolonged stable disease after disease progression on prior therapies. As no randomized trials are currently planned with this agent in WDLS/DDLS, and in the absence of any other active agents, off-label use of this agent remains a consideration. It remains to be determined whether this agent will be added to National Comprehensive Cancer Network Drugs & Biologics Compendium now that it is approved for patients with ER-positive breast cancer. Although MDM2 inhibitors have been successful in stabilizing tumors in WDLS and DDLS, the hematologic side effects, especially thrombocytopenia, remain a major hurdle in drug development. The key to advancement of MDM2 inhibitors in the clinic is to balance effıcacy with hematologic toxicity. This may be accomplished by optimizing scheduling such that effıcacious pharmacokinetics are achieved without appreciable toxicity.
Although these subtype-specifıc treatments should be viewed as signs of progress in the treatment of patients with liposarcomas, key challenges remain. First, targeting MDM2 and CDK4 in patients with WDLS and DDLS generally does not result in responses, but rather in disease stabilization. Recent reports of proteolytic turnover of MDM2 protein in the setting of CDK4 inhibition and the role of ATRX in cellular senescence versus quiescence may shed more light on the key mechanisms involved in CDK4/6 inhibitor response. This may ultimately provide a means to identify which patients will respond best to this type of targeted therapy. Second, since both WDLS and DDLS contain MDM2 and CDK4 amplifıcation/overexpression, these changes solely cannot explain the aggressiveness of DDLS. The molecular switch or switches that convert WDLS to DDLS require investigation. Third, the molecular pathways that drive this class of diseases, especially PLS, need to be further interrogated to identify actionable targets in these disease subtypes. Owing to their heterogeneity and diverse underlying molecular mechanisms that drive growth, it is not surprising that liposarcoma subtypes respond differently to distinct treatments. This genetic diversity provides unique opportunities in drug development and has provided patients with liposarcoma new hope in treatment of their disease.
